Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) – Pipeline Review, H1 2018

According to the recently published report 'Nuclear Receptor ROR Gamma – Pipeline Review, H1 2018'; Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) pipeline Target constitutes close to 37 molecules. Out of which approximately 34 molecules are developed by companies and remaining by the universities/institutes.

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) – RAR-related orphan receptor gamma (RORγ) is a protein encoded by the RORC gene. RORγ is member of the nuclear receptor family of transcription factors. It exist in two isoforms RORγ and RORγt. RORγ is expressed in many tissues, including thymus, lung, liver, kidney, muscle, and brown fat. R ORγt, appears to be highly restricted to the thymus. RORγ isoform is involved in the regulation of circadian rhythms and RORγt plays an important regulatory role in thymopoiesis and in inhibiting apoptosis.

The report 'Nuclear Receptor ROR Gamma – Pipeline Review, H1 2018' outlays comprehensive information on the Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 3, 1, 20, 6 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Immunology, Central Nervous System, Gastrointestinal, Musculoskeletal Disorders, Oncology, Dermatology, Respiratory, Metabolic Disorders and Other Diseases which include indications Psoriasis, Rheumatoid Arthritis, Inflammation, Autoimmune Disorders, Multiple Sclerosis, Inflammatory Bowel Disease, Psoriatic Arthritis, Plaque Psoriasis (Psoriasis Vulgaris), Non-Alcoholic Steatohepatitis (NASH), Allergies, Ankylosing Spondylitis (Bekhterev's Disease), Arthritis, Asthma, Axial Spondyloarthritis, Bladder Cancer, Breast Cancer, Chronic Obstructive Pulmonary Disease (COPD), Encephalomyelitis, Esophageal Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Kidney Cancer (Renal Cell Cancer), Neuromyelitis Optica (Devic’s Syndrome), Non-Small Cell Lung Cancer, Orphan Diseases, Ovarian Cancer, Skin Inflammation, Systemic Lupus Erythematosus and Type 1 Diabetes (Juvenile Diabetes).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC)

– The report reviews Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics and enlists all their major and minor projects

– The report assesses Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AbbVie Inc

Allergan Plc

Arrien Pharmaceuticals LLC

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Beijing Hanmi Pharmaceutical Co Ltd

Biogen Inc

Brickell Biotech Inc

Bristol-Myers Squibb Co

Celgene Corp

Eli Lilly and Co

Genentech Inc

Genfit SA

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Lead Pharma Holding BV

Lycera Corp

Maruho Co Ltd

Novartis AG

Nuevolution AB

Orphagen Pharmaceuticals Inc

Phenex Pharmaceuticals AG

Reata Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Overview

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Companies Involved in Therapeutics Development

AbbVie Inc

Allergan Plc

Arrien Pharmaceuticals LLC

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Beijing Hanmi Pharmaceutical Co Ltd

Biogen Inc

Brickell Biotech Inc

Bristol-Myers Squibb Co

Celgene Corp

Eli Lilly and Co

Genentech Inc

Genfit SA

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Lead Pharma Holding BV

Lycera Corp

Maruho Co Ltd

Novartis AG

Nuevolution AB

Orphagen Pharmaceuticals Inc

Phenex Pharmaceuticals AG

Reata Pharmaceuticals Inc

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Drug Profiles

ARN-6039 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-0284 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BBI-6000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GRC-39815 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2981278 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMU-366 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INV-17 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INV-71 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-3534 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JTE-451 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LYC-55716 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LYC-56056 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ROR-Gamma for Inflammation and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ROR-Gamma for Multiple Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ROR-Gamma for Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit ROR Gamma for Autoimmune Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit ROR-Gamma T for Autoimmune Disorders and Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit RORC for Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target ROR Gamma for Autoimmune Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize RAR-Related Orphan Receptor Gamma for Inflammatory Bowel Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize ROR gamma for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize ROR-Gamma for Autoimmune Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize ROR-Gamma for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RORC for Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RORc for Autoimmune Diseases and Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis and Non-Alcoholic Steatohepatitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis, Non-Alcoholic Steatohepatitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RORC for Psoriasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RORgamma for Rheumatoid Arthritis, Inflammatory Bowel Disease, Dermatology and Psoriatic Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ROR gamma-t for Autoimmune Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ROR Gamma-t for Multiple Sclerosis and Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SR-1001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SR-2211 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TGFTX-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TMP-778 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VPR-66 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VTP-43742 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Dormant Products

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Discontinued Products

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Product Development Milestones

Featured News & Press Releases

Jan 04, 2018: Lycera Announces Initiation of Phase 1b Study of Novel Immuno-Oncology Candidate LYC-55716 in Combination with Pembrolizumab

Nov 21, 2017: Lead Pharma Achieves Third Milestone in Sanofi Collaboration for Development of Autoimmune Diseases Treatments

Nov 07, 2017: Lycera Presents Tumor Selection Rationale for Phase 2a Study at Society for Immunotherapy of Cancer’s (SITC) 2017 Annual Meeting for RORgamma Agonist, LYC-55716

Oct 04, 2017: Exelixis to Receive Milestone Payment from Bristol-Myers Squibb for Submission of Clinical Trial Authorization for RORC Inverse Agonist Program

Sep 11, 2017: Lycera Presents Encouraging Safety Results from Phase 1 ARGON Study of LYC-55716 at the European Society for Medical Oncology (ESMO) Congress

Jul 10, 2017: Phenex announces milestone payment from Janssen for the entry of RORgt inhibitor into Phase I

Jan 04, 2017: Lycera Announces Initiation of Phase 1/2a Study ARGON of Immuno-Oncology Candidate LYC-55716 in Patients with Advanced Solid Tumors

Nov 04, 2016: Lycera Announces Publication of Immuno-Oncology Research, Demonstrating Differentiated Mechanism of RORgamma Agonists

Sep 26, 2016: GENFIT: Successful identification of RORt inverse agonists as candidates for regulatory pre-IND studies

Aug 01, 2016: Arrien Pharmaceuticals Provides Update on ARN-6039

Jun 06, 2016: Vitae Pharmaceuticals Announces Appointment of Carole Sable, M.D., as Chief Medical Officer

Jun 03, 2016: Arrien Pharmaceuticals Initiated Phase I Clinical Trials of ARN-6039 as a New Agent for Treatment of Multiple Sclerosis

May 16, 2016: Arrien Pharmaceuticals Initiates Phase I Clinical trials of ARN-6039

May 09, 2016: Arrien Pharmaceuticals to Initiate the Phase I Clinical trials of Autoimmune Drug

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1)

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by AbbVie Inc, H1 2018

Pipeline by Allergan Plc, H1 2018

Pipeline by Arrien Pharmaceuticals LLC, H1 2018

Pipeline by AstraZeneca Plc, H1 2018

Pipeline by Aurigene Discovery Technologies Ltd, H1 2018

Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H1 2018

Pipeline by Biogen Inc, H1 2018

Pipeline by Brickell Biotech Inc, H1 2018

Pipeline by Bristol-Myers Squibb Co, H1 2018

Pipeline by Celgene Corp, H1 2018

Pipeline by Eli Lilly and Co, H1 2018

Pipeline by Genentech Inc, H1 2018

Pipeline by Genfit SA, H1 2018

Pipeline by GlaxoSmithKline Plc, H1 2018

Pipeline by Glenmark Pharmaceuticals Ltd, H1 2018

Pipeline by Lead Pharma Holding BV, H1 2018

Pipeline by Lycera Corp, H1 2018

Pipeline by Maruho Co Ltd, H1 2018

Pipeline by Novartis AG, H1 2018

Pipeline by Nuevolution AB, H1 2018

Pipeline by Orphagen Pharmaceuticals Inc, H1 2018

Pipeline by Phenex Pharmaceuticals AG, H1 2018

Pipeline by Reata Pharmaceuticals Inc, H1 2018

Dormant Projects, H1 2018

Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports